# A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.

> **NCT01266941** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 35 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Inhaled FF 200mcg/GW642444M 25mcg

## Key facts

- **NCT ID:** NCT01266941
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-18
- **Primary completion:** 2011-07-15
- **Final completion:** 2011-07-15
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266941, "A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01266941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*